POWAY, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Digirad Corporation , a leading provider of medical diagnostic imaging systems and services to physicians’ offices, hospitals and imaging centers, will showcase its latest work-in-progress during ACC.08, the American College of Cardiology’s 57th Annual Scientific Session and Exposition to be held March 29-April 1, 2008, in Chicago.
Digirad’s Cardius X-ACT(TM), a dedicated cardiac SPECT system, is expected to set a new clinical standard with X-ACT attenuation correction. The system uses the Cardius-3 XPO camera’s solid state detectors with an x-ray tube. The revolutionary X-ACT approach exploits the high-count rate capabilities of solid-state detectors and takes advantage of the full 24-inch-wide triple-head detector geometry to eliminate truncation. The imaging system offers the benefits of high precision, faster speed, low dose and superb reliability.
Digirad also recently released nSPEED, an advanced three-dimensional SPECT image reconstruction technique. This advanced algorithm provides clinicians with significant image quality improvement over existing 2D reconstruction techniques by producing images with better contrast and spatial resolution to help improve physicians’ interpretation confidence.
nSPEED rapid image-acquisition protocols have demonstrated equivalent diagnostic quality for stress and rest images in half the acquisition time of traditional 2D approaches while providing reliable function quantitation measurements from gated stress images and reliable quantitation of perfusion-defect severity on stress and rest images.
About Digirad Corporation
Digirad provides diagnostic medical imaging systems and services to physicians’ offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications. Digirad’s Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad’s 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad’s installed base of equipment exceeds 450 systems; in addition, a mobile fleet of more than 120 nuclear and ultrasound imaging systems is being used in 22 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit http://www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.
Forward Looking Statements
Digirad cautions that statements included in this press release that are not a description of historical facts are forward looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning in connection with future operating, financial or product performance or events. Examples of such statements include statements regarding features and performance of the X-ACT and nSPEED systems, physician and patient benefits. Actual performance and benefits results may differ materially from those set forth in this press release due to risks and uncertainties inherent in Digirad’s business including, without limitation, disruptions in business activities, suppliers, the use of Digirad’s camera systems by physicians, reliability, technical issues, recalls, and other risks detailed in Digirad’s filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward looking statements, which speak only as of the date hereof. All forward looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward looking statements contained herein.
CONTACT: Investors, Dan Matsui, d.matsui@allencaron.com, or Media, Len
Hall, len@allencaron.com, both of Allen & Caron, +1-949-474-4300, for
Digirad Corporation; or Randy Weatherhead, Sr. Vice President of Sales and
Marketing of Digirad Corporation, +1-858-726-1600, info@digirad.com
Web site: http://www.digirad.com/
